LONDON (Reuters) – Positive news on initial trials of the University of Oxford’s potential COVID-19 vaccine that has been licensed to AstraZeneca could be announced as soon as Thursday, ITV’s political editor Robert Peston said, citing a source.
The potential vaccine is already in large-scale Phase III human trials to assess whether it can protect against COVID-19, but its developers have yet to report Phase I results which would show whether it is safe and whether or not it induces an immune response.
The developers of the vaccine said this month they are encouraged by the immune response they have seen in trials so far and were expecting to be able to publish Phase 1 data by the end of July.
The data are expected to be published by The Lancet medical journal.
A spokeswoman for Oxford University told Reuters the team was awaiting confirmation from a scientific journal of a publication date and time for the data, but gave no further details. “(We) are not able to confirm when it will be released,” she said.
Peston said in a blog post: “I am hearing there will be positive news soon (perhaps tomorrow) on initial trials of the Oxford Covid-19 vaccine that is backed by AstraZeneca.”
More than 100 vaccines are being developed and tested around the world to try to stop the COVID-19 pandemic, which has killed hundreds of thousands and ravaged the global economy.